Similar Papers

Paper Title
Journal
Date
Author
Safety and Effectiveness of Apixaban, LMWH and Warfarin Among Venous Thromboembolism (VTE) Patients with Active Cancer: A Subgroup Analysis of VTE Risk Scale
Alexander T Cohen ... Xuemei Luo
Blood | VOL. 134
Alexander T Cohen, et. al.Alexander T Cohen ... Xuemei Luo
13 Nov 2019
Effectiveness and safety of apixaban, low-molecular weight heparin, and warfarin among high-risk subgroups of venous thromboembolism patients with active cancer
A Cohen ... P Hlavacek
European Heart Journal | VOL. 41
A Cohen, et. al.A Cohen ... P Hlavacek
01 Nov 2020
Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
Theodore Lee ... Lisa Rosenblatt
Thrombosis and haemostasis | VOL. 121
Theodore Lee, et. al.Theodore Lee ... Lisa Rosenblatt
10 Nov 2020
Effectiveness and safety of apixaban vs warfarin among older venous thromboembolism patients stratified by race
...
European Heart Journal | VOL. 42
, et. al. ...
12 Oct 2021
View more papers

More From: Blood

Paper Title
Journal
Date
Author
DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis.
Sebastiaan N J Laan ... Iris Van Moort
Blood | VOL. -
Sebastiaan N J Laan, et. al.Sebastiaan N J Laan ... Iris Van Moort
24 Jan 2025
The Fit Older Adult with Acute Myeloid Leukemia: Clinical Challenges to Providing Evidence-Based Frontline Treatment.
Sameem M Abedin ... Laura C Michaelis
Blood | VOL. -
Sameem M Abedin, et. al.Sameem M Abedin ... Laura C Michaelis
24 Jan 2025
One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying them.
Ainsley V.C Knox ... Neil Romberg
Blood | VOL. -
Ainsley V.C Knox, et. al.Ainsley V.C Knox ... Neil Romberg
24 Jan 2025
VenEx precisely predicts ven-aza response.
Pamela S Becker
Blood | VOL. 145
Pamela S BeckerPamela S Becker
23 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.